Skip To Main Content
Christina Szalinski on Muck Rack

Christina Szalinski

New York
As seen in: The New York Times, Wirecutter, Nature, WebMD, Cornell Chronicle, The Atlantic, Ars Technica, Chicago Tribune, Lifehacker, Scientific American and
Freelance writer with a PhD in cell bio. Focused on health, science, family & food. Bylines: The Atlantic, NYTimes, SciAm, Undark & more.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christina

Contact Christina, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Best Infant Car Seats

|
By Christina Szalinski
| Wirecutter Verified
Why you should trust us I am a freelance journalist with a PhD in cell biology whose reporting on health has appeared in Scientific American, Undark, and more. In addition to writing Wirecutter’s updated guides to infant car seats, convertible car seats, booster car seats, and travel car seats, I am responsible for its guides to the best baby formula and face masks for kids.
Open in Who Shared Issue with article?

The Best Convertible and All-in-One Car Seats

|
By Christina Szalinski
| Wirecutter Verified
Why you should trust us We interviewed safety authorities, engineers, and physicians, asking them to detail the most important safety and usability considerations for convertible and all-in-one car seats. We consulted Child Passenger Safety Technicians (CPSTs) and car-seat safety advocates, and we had an in-person meeting and assessment of the seat finalists with an injury-prevention expert.
Open in Who Shared Issue with article?

A New Class of Therapeutics Could End Immunosuppressants

|
By Christina Szalinski
| Medscape Verified
To manage autoimmune disease or prevent a transplant rejection, many patients must accept a lifelong trade-off: immunosuppressants reduce immediate threats but increase the risk for infection, cancer, heart disease, and kidney failure. New science may have found a better way — harnessing the immune system’s own regulatory T cells, or Tregs, to reset the immune system, triggering a long-term benefit without the need for continual drugs.
Open in Who Shared Issue with article?
See all 452 licensed articles (467 Total)